HighTower Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

HighTower Advisors’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-819	Closed	-$9K	–	3722
2022 Q4	$9K	Buy	819 +628	+329%	+$7.18K	﹤0.01%	3184
2022 Q3	$2K	Sell	191 -543	-74%	-$14K	﹤0.01%	3109
2022 Q2	$25K	Buy	734 +29	+4%	+$905	﹤0.01%	2978
2022 Q1	$27K	Buy	705 +143	+25%	+$6.14K	﹤0.01%	3135
2021 Q4	$23K	Sell	562 -424	-43%	-$26.4K	﹤0.01%	3099
2021 Q3	$66K	Buy	986 +812	+467%	+$59.4K	﹤0.01%	2909
2021 Q2	$13K	Buy	+174	New	+$10.6K	﹤0.01%	2984
2019 Q2	–	Sell	-174	Closed	-$27K	–	2541
2019 Q1	$27K	Hold	174	–	–	﹤0.01%	2169
2018 Q4	$28K	Hold	174	–	–	﹤0.01%	2067
2018 Q3	$44K	Buy	174 +4	+2%	+$947	﹤0.01%	2135
2018 Q2	$38K	Hold	170	–	–	﹤0.01%	2083
2018 Q1	$43K	Buy	170 +31	+22%	+$8.14K	﹤0.01%	2023
2017 Q4	$43K	Buy	+139	New	+$45.7K	﹤0.01%	2112
2016 Q2	–	Sell	-454	Closed	-$195K	–	2064
2016 Q1	$195K	Hold	454	–	–	﹤0.01%	1815
2015 Q4	$172K	Hold	454	–	–	﹤0.01%	1787
2015 Q3	$123K	Buy	+454	New	+$126K	﹤0.01%	1714
2015 Q2	–	Sell	-214	Closed	-$59K	–	1744
2015 Q1	$59K	Sell	214 -372	-63%	-$161K	﹤0.01%	1526
2014 Q4	$253K	Sell	586 -243	-29%	-$77.2K	﹤0.01%	1303
2014 Q3	$271K	Sell	829 -114	-12%	-$33.4K	﹤0.01%	1249
2014 Q2	$317K	Buy	+943	New	+$370K	0.01%	1230

Other funds holding DMK

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HighTower Advisors's DMK Position: Q1 2023 in Review

HighTower Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2023, closing a stake of 819 shares — an estimated $9K sold.

HighTower Advisors first reported a position in DMK in Q2 2014 and held it in 20 quarters. The position peaked at $317K in Q2 2014. 47 funds tracked by Wall St. Rank hold DMK as of Q1 2023.

HighTower Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2023 after selling out during the quarter.
HighTower Advisors sold 819 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2023, an estimated $9K.
HighTower Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2014 and held it in 20 quarters.
HighTower Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $317K in Q2 2014.
47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.